Dexcom (DXCM) is leveraging AI to drive operational efficiency and product innovation, positioning itself as a platform ...

What’s the next CGM step change, and how is Dexcom going to deliver it? That’s one of the fundamental questions Jake Leach has been asked since stepping into the role of CEO at Dexcom. “I want to make ...

DexCom's improved fundamentals and a 15% lower stock price present a more attractive entry. Learn why DXCM stock is a Buy.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...

The FDA has officially cleared the Dexcom G5 continuous glucose monitor to inform treatment decisions -- without the use of a fingerstick glucometer, other than for calibration. The G5 has been ...

Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists1. The new system will be available shortly. Dexcom ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

DexCom DXCM recently announced the launch of Dexcom Flex, a new continuous glucose monitoring (CGM) system designed for ...

When it comes to the diabetes space, Dexcom is one of the heavy hitters. Its work in the continuous glucose monitoring space has put it on the map. In 2018, its Dexcom G6, an integrated continuous ...